About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Guangzhou Women's Health Cohort Study (GWHCS) | Clinical Trials | Clareo Health

Back to clinical trial search

SUSPENDEDNCT05506800

Guangzhou Women's Health Cohort Study (GWHCS)

The Guangzhou Women's Health Cohort Study aims to explore the health trajectory and factors contributing to the health of women aged 35-64 in Guangzhou. Based on multiple population health registratio...

Lead sponsor: Guangzhou Women and Children's Medical Center•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Guangzhou Women and Children's Medical Center

The Guangzhou Women's Health Cohort Study aims to explore the health trajectory and factors contributing to the health of women aged 35-64 in Guangzhou. Based on multiple population health registration data platforms, data of the cohort will provide information about the health of women across the lifespan, facilitating the decision-making process by local government . The cohort is progressing steadily, and the goal is to build a large women cohort covering 11 administrative districts of Guangzhou with a scale of 1 million by 2030.

Age

35 - 64 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•Women aged 35-64 years old
•Women with registered permanent residence in Guangzhou
•Women with informed consent

Exclusion Criteria

•Women without informed consent
•Women with reading and/or writing difficulties
•Women with serious mental disorders

Related studies

RECRUITINGPhase 3

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137 · Non Small Cell Lung Cancer

HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity

NCT07586215 · Breast Cancer Metastatic

RECRUITINGPhase 3

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

NCT07005128 · Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer

RECRUITINGPhase 2

A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer

NCT07489716 · Non-Small Cell Lung Cancer

RC48-ADC in HER2-low Advanced Breast Cancer

NCT05831878 · Advanced Breast Cancer

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 23, 2023Terms

Trial snapshot

StatusSUSPENDED

Phase—

Enrollment1,000,000

Start dateMar 2016

Last updatedFeb 23, 2023

Condition

Cervical Cancer Breast Cancer Lung Cancer Colorectal Cancer Endometrial Cancer+4 more

Locations shown

Guangzhou Women and Children's Medical Center

Guangzhou, Guangdong

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 23, 2023Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions